The longevity-focused biopharma delivered mixed results in its first clinical trial in humans.
Investors have had to withstand above-average volatility with these two stocks in recent years, but better days are on the horizon.
A new day, a new batch of promising interim data from an early-stage clinical study.
The lithium producer has big growth plans, but the renewable power asset manager has ambitions of its own.
The stock soared to its highest level in over 10 years on encouraging, early-stage clinical results.
Investors just received some bad news about the company's lead drug candidate.
The new materials science company is eager to deliver consistent performance -- and a 6% annual dividend yield -- courtesy of its far-reaching product portfolio.
The stock rose after a promising full-year 2018 earnings report and then rapidly began sliding back to multiyear lows. What's going on?
The company reported disappointing interim data from an ongoing phase 2b trial in NASH, but it wasn't all bad news.
Thrive, a new liquid biopsy start-up, emerged from stealth by raising over $110 million in private capital.
The new specialty materials company will have the highest operating margin of the three DowDuPont spinoffs.
Precision BioSciences raised over $170 million in net proceeds from its initial public offering in late March.
The company's shares are flying high once again, but there's a catch.
Investors continued to sell the news of a weak Q1 earnings report, but management made things worse with a controversial acquisition.
The biotech expects double-digit revenue growth in 2019, but shares have fallen 21% since the end of March.
The fertilizer stock rose steadily throughout 2018, but has plummeted this year. What's going on?
The global healthcare services company reported quarterly earnings and a sharp drop in operating income.
The small-cap biopharma started 2019 with a rising stock price and a new focus on gene therapies, but it's been a rocky transition.
One great growth stock and one great income stock to anchor your portfolio's long-term performance.
The world's second largest agrochemical name is finally an independent company.